ATRA

Atara Biotherapeutics (ATRA)

About Atara Biotherapeutics (ATRA)

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Details

Daily high

$5.00

Daily low

$4.52

Price at open

$4.72

52 Week High

$19.14

52 Week Low

$4.25

Market cap

32.7M

Dividend yield

0.00%

Volume

509,376

Avg. volume

677,287

P/E ratio

2.07

Atara Biotherapeutics News